The presently accessible markers for PDAC, such as cancer antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), exhibit limited sensitivity for the purpose of PDAC screening, particularly during the first phases. This evidence concerns the gene CEACAM5 and cancer.